US biotechs may withhold drugs from Italy
This article was originally published in Scrip
Celgene and Biomarin would consider withholding new products from launch in Italy because of the hostile pricing environment there, and the impact on margins in other countries through reference pricing. BioMarin focuses on rare and orphan diseases, while Celgene specialises in oncology, haematology and inflammation/immunology. Both have a number of products in their late-stage pipeline.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.